Shots:

• The Center for iPS Cell Research and Application (CiRA) to transfer first T-CiRA cell therapy program to Takeda for its clinical development and the partners will continue to collaborate till CiRA develops 5 iCART program- planned to enter in clinical studies in 2021
• In 2015- CiRA and Takeda signed a 10yrs. research agreement to develop 12 iCART therapies under which Takeda got global rights to develop and commercialize the iCART product and CiRA got $160M as R&D funding and will receive development and regulatory milestones
• The iCART program is an induced pluripotent stem (iPS) cell-derived CART therapies which can be modified according to the patient’s need. In vivo preclinical studies demonstrated its robust antitumor efficacy along with CD19-targeted iCART

Click here to read full press release/ article | Ref: Takeda | Image: Officelovin